The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | An analysis on patients with high-risk multiple myeloma
Ankit Kansagra, MD, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, shares some highlights from his presentation made at the 2021 ASH conference. Dr Kansagra discusses results from an analysis that evaluated the outcomes of individuals with functional and cytogenetic high-risk myeloma. Using data from the COTA database, Dr Kansagra explains some important observations that were made. He draws focus on risk factors that may predict the likelihood of early relapse, the benefits observed when using daratumumab and autologous stem cell transplant (ASCT) in treatment regimens, and how this data may benefit future clinical trials for high-risk myeloma patients. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
Disclosures
Medical Advisory Board: Abbvie, Alynylam, BMS, Cota Health, GSK, Janssen, Oncopeptide, Takeda
